The full content of Annals is available to subscribers

Subscribe/Learn More  >
Therapeutics |

Review: Recombinant human erythropoietin decreases the need for blood transfusions and may delay dialysis in chronic renal failure

Steven Fishbane, MD
[+] Article, Author, and Disclosure Information

Sources of funding: Janssen Cilag and Scottish Office Department of Health.

For correspondence: Ms. J. Cody, University of Aberdeen, Aberdeen, Scotland, UK. E-mail j.cody@abdn.ac.uk.

Ann Intern Med. 2002;136(3):85. doi:10.7326/ACPJC-2002-136-3-085
Text Size: A A A

Question: In patients with chronic renal failure (CRF) and renal anemia, does recombinant human erythropoietin (rHu EPO) delay the need for dialysis?

Data sources: Studies were identified by searching 13 databases, including MEDLINE (1980 to May 2001), EMBASE/Excerpta Medica (1984 to June 2001), and the Cochrane Controlled Trials Register; hand searching Kidney International; scanning reference lists of relevant articles, reviews, and book chapters; searching the Internet; and contacting experts in the field and at relevant biomedical companies.

Study selection: Studies were selected if they were randomized controlled trials (RCTs) or quasi-RCTs that compared rHu EPO with placebo or no rHu EPO in patients with CRF and renal anemia who had not started dialysis.

Data extraction: 2 investigators independently assessed trials for methodologic quality and subject relevance. Data were extracted on participants, intervention, and outcomes (time to dialysis, glomerular filtration rate [GFR], serum creatinine level, hemoglobin or hematocrit values, blood transfusions, quality-of-life measures, hypertension, other adverse events, and mortality).

Main results: 12 RCTs (232 patients) were included. 9 trials were 8 to 12 weeks in duration; 3 trials ranged from 36 weeks to 1 year. 5 trials reported progression of renal failure; groups did not differ for the proportion of patients starting dialysis (Table). The groups did not differ for GFR (4 trials) (weighted mean difference [WMD] 1.59 mL/min, 95% CI −0.49 to 3.66) or serum creatinine levels (5 trials) (WMD 76.12 µmol/L, CI −7.94 to 160.17). Fewer patients who received rHu EPO required blood transfusions (Table). 1 trial that measured hemoglobin level showed that rHu EPO was beneficial (mean difference 2.3 g/dL, CI 1.37 to 3.23), and 7 trials showed a benefit of rHu EPO in increasing hematocrit levels (WMD 9.92%, CI 8.7% to 11.05%). 2 trials that measured quality of life showed improvement with rHu EPO at 12 and 48 weeks. More patients who received rHu EPO had to start antihypertensive therapy than did control-group patients (Table). Incidences of withdrawal because of adverse effects (4 trials) and mortality (3 trials) were low and did not differ between groups.

Conclusion: In patients with chronic renal failure and renal anemia, recombinant human erythropoietin corrects anemia and reduces the need for blood transfusions but increases blood pressure and does not reduce the need to start dialysis.

Recombinant human erythropoietin (rHu EPO) vs placebo or no rHu EPO (control) for chronic renal failure with renal anemia*

Outcomes at 8 wk to 1 yNumber of trialsWeighted event ratesRRR (95% CI)NNT (CI)
rHu EPOControl
Dialysis531%43%28% (−3 to 50)Not significant
Blood transfusion37.0%26%69% (21 to 88)6 (3 to 23)
Antihypertensive therapy447%33%42% (0 to 102)8 (4 to 100)

*Abbreviations defined in Glossary; RRR, RRI, NNT, NNH, and CI calculated from data in article using a fixed-effects model.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.